agmb-129
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2023 (NCT05843578)
Timeline
Indications
Mechanism of action
- TGF-beta receptor type IINHIBITOR
TGFBR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07118878 | Phase 1 | Aug 6, 2025 | Agomab |
| NCT06397508 | Phase 1 | Apr 2, 2024 | Agomab |
| NCT05937386 | Phase 1 | Aug 9, 2023 | Agomab |
| NCT05843578 | Phase 2 | Aug 1, 2023 | Agomab |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Agomab | For profit | 4 | 4 | 2 | 2023 |
1 organizations
Page 1 / 1